Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 251–260 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 251
- Medicine slug
- carbamazepine
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 91
- Source count
- 74
- Agreement rate
- 1
- Recorded readings
89%
- Numeric value
- 89
- Unit
- %
- Source records
- 74
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 74 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32dc301e-881d-47b0-ad16-f9ff31d19324 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45b355e6-9c19-4138-a1f8-53508e88f5a9 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e006049f-1c0c-4544-969e-0344d1b8c5ba (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the XR tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b563e4a1-d7dd-4901-ad45-614f85687589 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:544e3b55-c8a3-a480-e063-6394a90abbb5 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the XR tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8cc7288c-4a7e-417c-9ceb-0e0f8aeeacb3 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a8c7366-ce89-47ce-8123-96f26812fca0 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f3d91cd-a959-4e07-a51b-8a4e9ba9ece2 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the XR tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52cf3ba9-0a7c-4809-830e-af93d1532726 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:232ef732-ee6d-4ac7-8e78-c619b611fbbe (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e68998cb-5f91-4d7e-85a6-555efb8b0384 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the XR tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:697f3e5a-c84b-44a6-b9f3-15e7d9bb6395 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a742c03d-10b1-48e2-8df1-48967395ae06 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the XR tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40bf2923-24b1-4af1-8d20-03cf06b455a5 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c91a5a1b-5481-445b-86e8-f10109ac3937 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0a254c5-bd33-4b14-b9f0-830b3438f5c6 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1fc170d7-db1a-486d-8c10-faa6e3da3b1e (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1fc31ef-6b2e-4de4-a185-ec44e94e7b40 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25939406-a836-43cd-9301-56808e9b31ec (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9fca7d59-dd9e-4fd8-bf34-e2f7e5a36801 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34f57a68-57ad-57f1-e063-6394a90a3d33 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20cd4276-afb1-43e5-abb3-e2af7f8a71dd (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46a9771e-5830-4905-b5fc-5d1c61fd56a0 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f9535b1-ff6a-41b3-bbb2-efcf8fbacf4c (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf1590a0-68a7-45ed-817e-f97366f96ec4 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5461e739-0f18-b012-e063-6394a90a6b14 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:282c954f-e34a-4bd5-b5eb-771e3c56936f (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3465f71-8931-43b6-baea-eac7046a4400 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the XR tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d5ace90-983b-48c4-baf1-b44f6af146de (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the XR tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30b75584-3a1c-c125-e063-6294a90acaa7 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35298eaf-3478-4dfb-a629-298dd52713f0 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the XR tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62d38b93-7dd0-48e7-bd59-a434d52520f6 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the XR tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1dc2a4d3-2ebc-4c9b-a347-92acd9f231f2 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e3c4854-89a1-4e3f-88d4-e164829585fb (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0121be3-b904-41d3-a81a-292aa4176491 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9471b7fb-29d3-4009-9d0f-f20c27351db5 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97e6e175-75e8-437b-b457-ddb1ae4e857d (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf0d012f-da14-8ce3-d74f-56172cddebc5 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b48741b3-0889-47b8-a26e-b12614f6e7fc (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8444c23-a74f-4d44-867e-26554dbb882f (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b56dd9c8-1bca-21e3-e053-2995a90a3e6e (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the XR tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce5aec7a-e161-46bf-8fc0-afb41689e59a (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3cd36c4-b25e-4716-be1d-0b2c83ea6a03 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7108d630-89bc-4815-b6fb-a1f4676c496e (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48080efd-1781-4585-83f8-c43957ac63b3 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d409411-aa9f-4f3a-a52c-fbcb0c3ec053 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the XR tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5e4a25a-0137-4327-96f5-15735891ad5c (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a1ce79d-18ea-f30b-e053-2995a90ad1fb (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c1dd8ce-c490-40b4-b17a-da331df24cba (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:536811ab-308b-4866-9185-9e4149483512 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd8b51f4-8427-4b18-9d2c-10771d2a6580 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:138d9ed1-2f8e-d19d-e063-6394a90a695d (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d10e5f83-56db-4bc9-8c51-150a2e3e20ea (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:867a5f4d-8ae6-4339-bbb4-0bf62fb082e5 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the XR tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:726a127b-03b2-44e8-a63d-078b35e27525 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41157f3e-61c4-1cbd-e063-6294a90a219f (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34b375d0-68b0-4bd5-8ac9-be043b57e91c (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:963db7cf-e9f5-496c-816e-626e89bc839e (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c72a0668-7cd7-46a8-86d1-d3c17c4b900f (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:509bd024-9944-a2f3-e063-6394a90ae4cb (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87b87b57-021a-4cb2-9edd-6efa732c208f (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ebcffad6-da03-43f4-a75b-7de13e94bb7d (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de67de85-15b3-4c27-b604-d028ce3789d0 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0526a054-3eda-49b4-b390-7d5d16e30af8 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3207764f-0663-477e-ad1f-f5fb43b6bbf3 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50ba2042-fc67-4266-a773-a30f07649a5a (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c4860c1-daba-4e0f-97fd-d30cbc8603a2 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1922a7cd-6a43-dab5-e063-6294a90a3d8f (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10c9795e-358c-4f6a-b7bc-cccc179617c0 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf61798e-c07e-4959-909a-2b4c2c83b532 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1dd3d934-efee-4fdb-ae6f-f47b61831a2e (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:047bc284-060a-4db9-bf37-75d10f95a0a6 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the XR tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d2c5317-4072-477b-a4e2-f6765fc71657 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the extended-release tablet was 89% compared to suspension.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87d343a8-84d5-4cdd-b0a0-629311b51f11 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The bioavailability of the XR tablet was 89% compared to suspension.
Projected row 252
- Medicine slug
- carbamazepine
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 91
- Source count
- 91
- Agreement rate
- 0.791209
- Recorded readings
25 to 65 hours
- Numeric value
- 25
- Unit
- hours
- Source records
- 72
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 72 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32dc301e-881d-47b0-ad16-f9ff31d19324 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45b355e6-9c19-4138-a1f8-53508e88f5a9 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e006049f-1c0c-4544-969e-0344d1b8c5ba (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b563e4a1-d7dd-4901-ad45-614f85687589 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:544e3b55-c8a3-a480-e063-6394a90abbb5 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8cc7288c-4a7e-417c-9ceb-0e0f8aeeacb3 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a8c7366-ce89-47ce-8123-96f26812fca0 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f3d91cd-a959-4e07-a51b-8a4e9ba9ece2 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52cf3ba9-0a7c-4809-830e-af93d1532726 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:232ef732-ee6d-4ac7-8e78-c619b611fbbe (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e68998cb-5f91-4d7e-85a6-555efb8b0384 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:697f3e5a-c84b-44a6-b9f3-15e7d9bb6395 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a742c03d-10b1-48e2-8df1-48967395ae06 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40bf2923-24b1-4af1-8d20-03cf06b455a5 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c91a5a1b-5481-445b-86e8-f10109ac3937 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0a254c5-bd33-4b14-b9f0-830b3438f5c6 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1fc170d7-db1a-486d-8c10-faa6e3da3b1e (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1fc31ef-6b2e-4de4-a185-ec44e94e7b40 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25939406-a836-43cd-9301-56808e9b31ec (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9fca7d59-dd9e-4fd8-bf34-e2f7e5a36801 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34f57a68-57ad-57f1-e063-6394a90a3d33 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20cd4276-afb1-43e5-abb3-e2af7f8a71dd (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46a9771e-5830-4905-b5fc-5d1c61fd56a0 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f9535b1-ff6a-41b3-bbb2-efcf8fbacf4c (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf1590a0-68a7-45ed-817e-f97366f96ec4 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5461e739-0f18-b012-e063-6394a90a6b14 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3465f71-8931-43b6-baea-eac7046a4400 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d5ace90-983b-48c4-baf1-b44f6af146de (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:30b75584-3a1c-c125-e063-6294a90acaa7 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35298eaf-3478-4dfb-a629-298dd52713f0 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62d38b93-7dd0-48e7-bd59-a434d52520f6 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1dc2a4d3-2ebc-4c9b-a347-92acd9f231f2 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0121be3-b904-41d3-a81a-292aa4176491 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9471b7fb-29d3-4009-9d0f-f20c27351db5 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97e6e175-75e8-437b-b457-ddb1ae4e857d (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf0d012f-da14-8ce3-d74f-56172cddebc5 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b48741b3-0889-47b8-a26e-b12614f6e7fc (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8444c23-a74f-4d44-867e-26554dbb882f (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b56dd9c8-1bca-21e3-e053-2995a90a3e6e (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce5aec7a-e161-46bf-8fc0-afb41689e59a (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3cd36c4-b25e-4716-be1d-0b2c83ea6a03 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7108d630-89bc-4815-b6fb-a1f4676c496e (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48080efd-1781-4585-83f8-c43957ac63b3 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d409411-aa9f-4f3a-a52c-fbcb0c3ec053 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5e4a25a-0137-4327-96f5-15735891ad5c (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a1ce79d-18ea-f30b-e053-2995a90ad1fb (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c1dd8ce-c490-40b4-b17a-da331df24cba (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:536811ab-308b-4866-9185-9e4149483512 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd8b51f4-8427-4b18-9d2c-10771d2a6580 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:138d9ed1-2f8e-d19d-e063-6394a90a695d (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d10e5f83-56db-4bc9-8c51-150a2e3e20ea (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:867a5f4d-8ae6-4339-bbb4-0bf62fb082e5 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:726a127b-03b2-44e8-a63d-078b35e27525 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41157f3e-61c4-1cbd-e063-6294a90a219f (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34b375d0-68b0-4bd5-8ac9-be043b57e91c (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:963db7cf-e9f5-496c-816e-626e89bc839e (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c72a0668-7cd7-46a8-86d1-d3c17c4b900f (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:509bd024-9944-a2f3-e063-6394a90ae4cb (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87b87b57-021a-4cb2-9edd-6efa732c208f (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ebcffad6-da03-43f4-a75b-7de13e94bb7d (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de67de85-15b3-4c27-b604-d028ce3789d0 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0526a054-3eda-49b4-b390-7d5d16e30af8 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3207764f-0663-477e-ad1f-f5fb43b6bbf3 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50ba2042-fc67-4266-a773-a30f07649a5a (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c4860c1-daba-4e0f-97fd-d30cbc8603a2 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1922a7cd-6a43-dab5-e063-6294a90a3d8f (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10c9795e-358c-4f6a-b7bc-cccc179617c0 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf61798e-c07e-4959-909a-2b4c2c83b532 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1dd3d934-efee-4fdb-ae6f-f47b61831a2e (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:047bc284-060a-4db9-bf37-75d10f95a0a6 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d2c5317-4072-477b-a4e2-f6765fc71657 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87d343a8-84d5-4cdd-b0a0-629311b51f11 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 to 65 hours, decreasing to 12 to 17 hours on repeated doses.
35 to 40 hours
- Numeric value
- 35
- Unit
- hours
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9d282f0-8bb7-4280-b83d-b70d83a04b93 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Following a single extended-release dose of carbamazepine, the average half-life range from 35 to 40 hours and 12 to 17 hours on repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1876184-0323-4b06-b459-603b40c0c002 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Following a single extended-release dose of carbamazepine, the average half-life range from 35-40 hours and 12-17 hours on repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be478f3c-40f6-47cc-8ab9-f420a9372b1c (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
The average half-life ranged from 35 to 40 hours following a single extended-release dose of carbamazepine and from 12 to 17 hours following repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4db57051-13bb-4038-ae58-e4d7f541450d (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Following a single extended-release dose of carbamazepine, the average half-life range from 35 to 40 hours and 12 to 17 hours on repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ccee1ed-3d7c-452b-9519-c1ddb92893df (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Following a single extended-release dose of carbamazepine, the average half-life range from 35 to 40 hours and 12 to 17 hours on repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33edb22f-f357-ec0f-e063-6394a90a7bc3 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Following a single extended-release dose of carbamazepine, the average half-life range from 35-40 hours and 12-17 hours on repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:34f75728-b9e8-48e7-e063-6394a90afc31 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Following a single extended-release dose of carbamazepine, the average half-life range from 35 to 40 hours and 12 to 17 hours on repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46eef194-760d-43ea-86c5-341927277c91 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Following a single extended-release dose of carbamazepine, the average half-life range from 35 to 40 hours and 12 to 17 hours on repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d684dfd8-1e0d-47a1-bf37-ada6413815f2 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Following a single extended-release dose of carbamazepine, the average half-life range from 35 to 40 hours and 12 to 17 hours on repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ceb84aa4-2041-6e6e-e053-2995a90a0f24 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Following a single extended-release dose of carbamazepine, the average half-life range from 35 to 40 hours and 12 to 17 hours on repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc03e499-5bac-4293-bff4-6864153a624d (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Following a single extended-release dose of carbamazepine, the average half-life range from 35-40 hours and 12-17 hours on repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a8c4f15-9e75-4919-ac67-06102b82dd92 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Following a single extended-release dose of carbamazepine, the average half-life range from 35 to 40 hours and 12 to 17 hours on repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d936849-9c80-5b7f-e063-6294a90aaa6c (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Following a single extended-release dose of carbamazepine, the average half-life range from 35-40 hours and 12-17 hours on repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33ed4e35-8be2-d0ea-e063-6394a90a06a6 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Following a single extended-release dose of carbamazepine, the average half-life range from 35-40 hours and 12-17 hours on repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e91f9de3-3fdd-0a6b-71ce-53a2cc142816 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Following a single extended-release dose of carbamazepine, the average half-life range from 35 to 40 hours and 12 to 17 hours on repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47d0ea82-9974-4d41-9ae1-5f1b11419a33 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Following a single extended-release dose of carbamazepine, the average half-life range from 35 to 40 hours and 12 to 17 hours on repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2676f950-48b4-4bef-a792-ea4570de9aa6 (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Following a single extended-release dose of carbamazepine, the average half-life range from 35 to 40 hours and 12 to 17 hours on repeated dosing.
25 hours
- Numeric value
- 25
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:282c954f-e34a-4bd5-b5eb-771e3c56936f (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 hours to 65 hours, decreasing to 12 hours to 17 hours on repeated doses.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e3c4854-89a1-4e3f-88d4-e164829585fb (opens source in a new tab)
Carbamazepine label
Version not recorded · Effective date not recorded
Initial half-life values range from 25 hours to 65 hours, decreasing to 12 hours to 17 hours on repeated doses.
Projected row 253
- Medicine slug
- carbinoxamine
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 9
- Source count
- 9
- Agreement rate
- 0.777778
- Recorded readings
10 to 20 hours
- Numeric value
- 10
- Unit
- hours
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:163db29b-f035-6696-e063-6294a90a7e06 (opens source in a new tab)
Carbinoxamine label
Version not recorded · Effective date not recorded
The serum half-life is reported to be 10 to 20 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a845fc15-c675-4e33-840c-6a74e79d0ced (opens source in a new tab)
Carbinoxamine label
Version not recorded · Effective date not recorded
The serum half-life is reported to be 10 to 20 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:02e13b55-2153-468e-a5bd-57dee062f47f (opens source in a new tab)
Carbinoxamine label
Version not recorded · Effective date not recorded
The serum half-life is reported to be 10 to 20 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:13ed76c7-49bd-4527-83dc-b4c7d0da9fff (opens source in a new tab)
Carbinoxamine label
Version not recorded · Effective date not recorded
The serum half-life is reported to be 10 to 20 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14266e97-674b-b6a9-37a2-a955f0a01c4f (opens source in a new tab)
Carbinoxamine label
Version not recorded · Effective date not recorded
The serum half-life is reported to be 10 to 20 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91ee2e99-082a-4157-b71b-1a7c0e5464fa (opens source in a new tab)
Carbinoxamine label
Version not recorded · Effective date not recorded
The serum half-life is reported to be 10 to 20 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d11b197-cfdc-4b9b-9935-2920ccb6e522 (opens source in a new tab)
Carbinoxamine label
Version not recorded · Effective date not recorded
The serum half-life is reported to be 10 to 20 hours.
17.0 hours
- Numeric value
- 17
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:199f46e5-6288-5627-e063-6294a90ae086 (opens source in a new tab)
Carbinoxamine label
Version not recorded · Effective date not recorded
The plasma half-life of carbinoxamine was 17.0 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c40b3f4e-2d71-41a1-a1fc-f64f38724879 (opens source in a new tab)
Carbinoxamine label
Version not recorded · Effective date not recorded
The plasma half-life of carbinoxamine was 17.0 hours.
Projected row 254
- Medicine slug
- carboplatin
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 14
- Source count
- 14
- Agreement rate
- 0.928571
- Recorded readings
5 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 13
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 13 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4fa7aac-c9d2-4af4-a281-3e6cfc502ff6 (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5abfcb87-bb02-4384-9c9d-7d0e3e809311 (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47677091-fd20-49af-933c-c9dd2be21de9 (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f64a0cbe-7fe3-407e-8933-21c30e1a1ebc (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c89cedc-e48b-445c-ad05-54dbe60e4fb0 (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3ae9880-44bb-4f4e-93d8-8a5e21708a30 (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5fe9a20-47a5-45b9-ab06-c6158d9b6aca (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c275825-0275-4c73-b650-e4c1519f13b8 (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e176b6ef-2ff6-498b-a9d8-7a634d147f37 (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f330f5a2-2cad-402f-bcbb-26245a753276 (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9eb057eb-29ce-40d2-9ac8-ed107f25f5ab (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5484d2f0-0cc2-4bba-8f26-c7f6539a9606 (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48aa7ef3-9f44-2a08-e054-00144ff88e88 (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days.
2.6 to 5.9 hours
- Numeric value
- 2.6
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f91c48da-68d1-4aa7-89b8-d84a3e8b629b (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
Elimination The elimination half-life is 2.6 to 5.9 hours and the total body clearance is 4.4 L/hour.
Projected row 255
- Medicine slug
- carboplatin
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 14
- Source count
- 14
- Agreement rate
- 0.928571
- Recorded readings
4.4 L
- Numeric value
- 4.4
- Unit
- L
- Source records
- 13
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 13 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4fa7aac-c9d2-4af4-a281-3e6cfc502ff6 (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5abfcb87-bb02-4384-9c9d-7d0e3e809311 (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:47677091-fd20-49af-933c-c9dd2be21de9 (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f64a0cbe-7fe3-407e-8933-21c30e1a1ebc (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c89cedc-e48b-445c-ad05-54dbe60e4fb0 (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/h, 16 L and 3.5 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3ae9880-44bb-4f4e-93d8-8a5e21708a30 (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5fe9a20-47a5-45b9-ab06-c6158d9b6aca (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1c275825-0275-4c73-b650-e4c1519f13b8 (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e176b6ef-2ff6-498b-a9d8-7a634d147f37 (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f330f5a2-2cad-402f-bcbb-26245a753276 (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9eb057eb-29ce-40d2-9ac8-ed107f25f5ab (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5484d2f0-0cc2-4bba-8f26-c7f6539a9606 (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48aa7ef3-9f44-2a08-e054-00144ff88e88 (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively.
16 L
- Numeric value
- 16
- Unit
- L
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f91c48da-68d1-4aa7-89b8-d84a3e8b629b (opens source in a new tab)
Carboplatin label
Version not recorded · Effective date not recorded
Distribution The volume of distribution is 16 L.
Projected row 256
- Medicine slug
- carglumic-acid
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 4
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
10%
- Numeric value
- 10
- Unit
- %
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59e73eb8-edf8-4fad-93c2-deb6b23497f8 (opens source in a new tab)
Carglumic Acid label
Version not recorded · Effective date not recorded
(L/hr/kg) 0.34 (0.02) N/A Vd (L/kg) 15 (1) N/A Absorption Following an oral administration of Carglumic acid tablets for oral suspension 100 mg/kg in healthy subjects, the absolute bioavailability was approximately 10%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2aee4281-402b-4cd6-9e6a-08945262e1a1 (opens source in a new tab)
Carglumic Acid label
Version not recorded · Effective date not recorded
(L/hr/kg) 0.34 (0.02) N/A Vd (L/kg) 15 (1) N/A Absorption Following an oral administration of Carglumic acid tablets for oral suspension 100 mg/kg in healthy subjects, the absolute bioavailability was approximately 10%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:591f95ca-3d99-4fb6-a402-e5a383a746d0 (opens source in a new tab)
Carglumic Acid label
Version not recorded · Effective date not recorded
N/A, not applicable Absorption Following an oral administration of Carglumic acid tablets for oral suspension 100 mg/kg in healthy subjects, the absolute bioavailability was approximately 10%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10175e73-5172-4dde-a508-8a88b7afc0a1 (opens source in a new tab)
Carglumic Acid label
Version not recorded · Effective date not recorded
0) T ½ (hr) 31 (3) 25 (2) CL (L/hr/kg) 0.34 (0.02) N/A Vd (L/kg) 15 (1) N/A Abso r p ti o n Following an oral administration of CARBAGLU 100 mg/kg in healthy subjects, the absolute bioavailability was approximately 10%.
Projected row 257
- Medicine slug
- carisoprodol
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 48
- Source count
- 47
- Agreement rate
- 1
- Recorded readings
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 47
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 47 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfb31551-8c57-4360-be3a-f6fbe84a891e (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:125023cb-45c2-1685-e063-6394a90af089 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35a8e0a4-93a3-44e3-903f-4661ee1cffe8 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c15f559-c045-4271-86ef-e001aad39c33 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:269644bf-d32c-48a3-b3eb-1221150ebd22 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:069ea892-21a6-4703-8dd3-bf19c4406479 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efd7a0b4-5ec5-4929-a4cb-7d207171eed6 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2178e805-8189-459f-a447-21bf1547744a (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Elimination: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ead8294f-fd27-5c3d-e053-2a95a90a64af (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c0c418c-90e2-4b81-a9c0-b131c38ec874 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:301f5e6a-54e1-4885-b9cb-de475de59b22 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4626a7a7-c433-4dab-8deb-e6e45de493a6 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd03c357-b199-c2b2-e053-6294a90abe2e (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f03a1ea6-20c1-406a-a5b6-00f1a056d9ff (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f6f0e3-fdbd-4788-9944-37edde4b9a3c (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eebb9409-e333-4b9f-8059-6588c35ab578 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5eff5b4c-c363-45b5-9eef-b724233a51e2 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d251c26-c893-425a-b8ac-20c06e50e80c (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2484de44-b36a-421c-a4d9-64c201694754 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4221d7d1-d7d6-46c4-be41-8c8e99129324 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95e13b8c-3558-43f0-b888-90978db878fb (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8aee817-c652-441e-b99a-8cbc4e6d06ef (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b83f7fd1-11e3-4e94-ae53-4637e892b372 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2179f18b-df15-4bf6-a7c7-6d9960f49a42 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93cbe188-5443-b392-e053-2995a90a9ac7 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Elimination: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f08f4af-37c2-49b5-a4e3-284414f866fa (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93f909ea-2d2e-4a10-be50-7f33f3e904d4 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94f74800-1f0d-7814-e053-2a95a90a4f63 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Elimination: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a44a3dfc-a427-4584-a086-4bc0c538b125 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Elimination: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c9184c0-7a2e-11df-8c8d-0002a5d5c51b (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b04fbd67-9ac5-4043-87e9-c3804d1e5d0c (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:acc7f959-55ac-4d9b-8ef4-4538378364e6 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:409b04af-b9fd-4ba5-afa0-3e43466f8d2d (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26e466be-8066-e562-e063-6394a90a9f81 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79637c7b-fe7b-436c-892b-6c36abfdcacc (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8079db44-70d4-4daf-b4b7-89d0e0f38470 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88f9b969-4225-49d6-9e4c-8c397ba7b50c (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6297cf20-830a-11dc-94c8-0002a5d5c51b (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2abd11e4-8ce4-4aeb-87c4-3af94c197714 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d2470cb-7a5d-45f0-b005-534458833d91 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b72ac75b-8c7c-4ec4-a7fa-b9c1a18f644c (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fdd6318f-399f-499c-acdc-5318aa080f36 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03c3455f-e217-4a7e-908f-609333dc35fc (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c6015ad-2158-400d-8c22-585ab277ea49 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f835e66e-f3f3-c3cf-e053-6294a90addf2 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e9bb49a-8cc3-4390-e053-2a95a90a4e0e (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Elimination: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3f1343f-1337-4b99-b1ae-4189324ec2e9 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
Excretion: Carisoprodol is eliminated by both renal and non-renal routes with a terminal elimination half-life of approximately 2 hours.
Projected row 258
- Medicine slug
- carisoprodol
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 48
- Source count
- 47
- Agreement rate
- 1
- Recorded readings
1.5 to 2 hours
- Numeric value
- 1.5
- Unit
- hours
- Source records
- 47
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 47 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfb31551-8c57-4360-be3a-f6fbe84a891e (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (Tmax) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:125023cb-45c2-1685-e063-6394a90af089 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:35a8e0a4-93a3-44e3-903f-4661ee1cffe8 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (Tmax) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c15f559-c045-4271-86ef-e001aad39c33 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:269644bf-d32c-48a3-b3eb-1221150ebd22 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:069ea892-21a6-4703-8dd3-bf19c4406479 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:efd7a0b4-5ec5-4929-a4cb-7d207171eed6 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2178e805-8189-459f-a447-21bf1547744a (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ead8294f-fd27-5c3d-e053-2a95a90a64af (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (Tmax) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c0c418c-90e2-4b81-a9c0-b131c38ec874 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (Tmax) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:301f5e6a-54e1-4885-b9cb-de475de59b22 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4626a7a7-c433-4dab-8deb-e6e45de493a6 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd03c357-b199-c2b2-e053-6294a90abe2e (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f03a1ea6-20c1-406a-a5b6-00f1a056d9ff (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f6f0e3-fdbd-4788-9944-37edde4b9a3c (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eebb9409-e333-4b9f-8059-6588c35ab578 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5eff5b4c-c363-45b5-9eef-b724233a51e2 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d251c26-c893-425a-b8ac-20c06e50e80c (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2484de44-b36a-421c-a4d9-64c201694754 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4221d7d1-d7d6-46c4-be41-8c8e99129324 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95e13b8c-3558-43f0-b888-90978db878fb (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8aee817-c652-441e-b99a-8cbc4e6d06ef (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b83f7fd1-11e3-4e94-ae53-4637e892b372 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2179f18b-df15-4bf6-a7c7-6d9960f49a42 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93cbe188-5443-b392-e053-2995a90a9ac7 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f08f4af-37c2-49b5-a4e3-284414f866fa (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (Tmax) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:93f909ea-2d2e-4a10-be50-7f33f3e904d4 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94f74800-1f0d-7814-e053-2a95a90a4f63 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a44a3dfc-a427-4584-a086-4bc0c538b125 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c9184c0-7a2e-11df-8c8d-0002a5d5c51b (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b04fbd67-9ac5-4043-87e9-c3804d1e5d0c (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:acc7f959-55ac-4d9b-8ef4-4538378364e6 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:409b04af-b9fd-4ba5-afa0-3e43466f8d2d (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (Tmax) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26e466be-8066-e562-e063-6394a90a9f81 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79637c7b-fe7b-436c-892b-6c36abfdcacc (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8079db44-70d4-4daf-b4b7-89d0e0f38470 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (Tmax) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88f9b969-4225-49d6-9e4c-8c397ba7b50c (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6297cf20-830a-11dc-94c8-0002a5d5c51b (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (Tmax) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2abd11e4-8ce4-4aeb-87c4-3af94c197714 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (Tmax) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d2470cb-7a5d-45f0-b005-534458833d91 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b72ac75b-8c7c-4ec4-a7fa-b9c1a18f644c (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fdd6318f-399f-499c-acdc-5318aa080f36 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03c3455f-e217-4a7e-908f-609333dc35fc (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7c6015ad-2158-400d-8c22-585ab277ea49 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f835e66e-f3f3-c3cf-e053-6294a90addf2 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e9bb49a-8cc3-4390-e053-2a95a90a4e0e (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (Tmax) of carisoprodol was approximately 1.5 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3f1343f-1337-4b99-b1ae-4189324ec2e9 (opens source in a new tab)
Carisoprodol label
Version not recorded · Effective date not recorded
The mean time to peak plasma concentrations (T max ) of carisoprodol was approximately 1.5 to 2 hours.
Projected row 259
- Medicine slug
- carvedilol
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 123
- Source count
- 123
- Agreement rate
- 1
- Recorded readings
25%
- Numeric value
- 25
- Unit
- %
- Source records
- 123
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 123 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe462198-32ae-4f6c-befc-acb97fb017c9 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b56e0d0-82d7-4512-849f-2b72d7bae36e (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:454054f1-0730-41b3-844a-c7b65f1b47c5 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol Tablet is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:63065e30-4a50-42b0-9622-a393923c1e98 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Carvedilol is rapidly and extensively absorbed following oral administration of immediate-release carvedilol tablets, with an absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c03bd9d7-1e0b-49da-a14a-32e712dc3a2d (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ccf07f5-78fb-76da-e053-2a95a90a0090 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cea10014-72b0-4190-a391-733c8912efe0 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Carvedilol is rapidly and extensively absorbed following oral administration of immediate-release carvedilol tablets, with an absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5822e3c-413c-4c7e-bbec-d0d42d2028ba (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:462a9678-d2cd-d2b8-e063-6294a90a0139 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
It also increases levels of atrial natriuretic peptide. 12.3 Pharmacokinetics Carvedilol Tablet is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c48ba6b-4e1e-5116-e063-6394a90aa793 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
It also increases levels of atrial natriuretic peptide. 12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce9623f8-6cea-45e0-a15c-2dd78690f2a7 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Carvedilol is rapidly and extensively absorbed following oral administration of immediate-release carvedilol tablets, with an absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd0f2596-a192-4b0e-836f-4a09816408a4 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb892787-edd0-4ab6-aef2-2d0216384395 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52bd1d20-08ba-1e5e-e063-6294a90ae8a9 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc3a9614-3017-4775-988e-6e5bd4621b70 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol Tablet is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84ee5fbf-7299-4b8a-e053-2a91aa0aa159 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac14846e-423a-37c4-e053-2a95a90a3cdd (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd7e7c34-6958-47be-a1c1-f1ed948e2687 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5e766e3-ef75-4100-e053-2995a90a510f (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
It also increases levels of atrial natriuretic peptide. 12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8640adde-d071-44a4-97d0-fa8a8548debe (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1be1b5d2-eb2c-1d02-e063-6294a90adbba (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Carvedilol is rapidly and extensively absorbed following oral administration of immediate-release carvedilol tablets, with an absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c133b9c7-ab1a-e517-e053-2995a90a517a (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db5d9e64-46b3-92d3-e053-2995a90a74bc (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol Tablet is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:574c419f-3b9e-2171-e063-6394a90a0e90 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58280d18-5960-1730-e063-6394a90a4f64 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95300809-be15-461e-904e-b56aba676975 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49afdf89-0bed-71da-e054-00144ff88e88 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36230cc8-e808-4f74-a27d-4367eecd21f7 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0ae5bed-1cb4-45d6-befe-dfc68edb9b34 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7bfd0fc-054b-7397-e053-2a95a90ae3e2 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol Tablet is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da2696ba-f4be-4626-9abe-fe33f36361b1 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2be8635b-5733-1ed4-e054-00144ff88e88 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8db9cddd-0ee7-4ce8-a8c9-c5e043b2838a (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ddff189-1848-4186-bca9-063e4ea7fd1f (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3625d78-6eb6-41fe-8f6f-664965c104c4 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Carvedilol is rapidly and extensively absorbed following oral administration of immediate-release carvedilol tablets, with an absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32098c09-7580-4975-a3e1-31b619c04c69 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e98593a-8424-48c8-acc0-671f4b566aee (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a570b8ea-530d-4565-a091-bb9dbe4a6d8d (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5969d18-46c7-4f35-9668-2fd4f6bbeb17 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0887c72-bc6a-010d-e053-2995a90aab8d (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:157f64c6-2c21-4056-b643-79047ca237a9 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:add1ee3d-fca4-4301-b871-7dda6eda7bb7 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bbf3767-8666-22d8-e063-6294a90a2afe (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:010290af-81f4-0037-e063-6394a90a4638 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03b7c07c-14ba-40c8-8c0a-8dfa4a10f580 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec6d8d73-9d18-4a9e-ae0c-0ea12059e78e (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab8aa773-0ed1-4d59-a1bb-f46cf882644f (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe2d5c95-c101-4b01-89fd-0fd6d25ad80b (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed60e2e4-6eda-4728-aec4-263b821e4ed8 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1344411-fc64-4233-89ba-e90a1953e150 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol Tablet is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81bc612d-5674-45b9-a1f5-2cb4fa625747 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64ba2b17-989e-443c-8277-9649489b5ce8 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a9314bc0-fd5d-477b-bef5-3bee532774c0 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Carvedilol is rapidly and extensively absorbed following oral administration of immediate-release carvedilol tablets, with an absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0617fa4-1e87-48fa-947a-e4249153a947 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:669ec7f8-f27d-4048-a784-00ca903cc658 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Carvedilol is rapidly and extensively absorbed following oral administration of immediate-release carvedilol tablets, with an absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa6b4014-e9d7-4074-95fc-4b48d91da83b (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Carvedilol is rapidly and extensively absorbed following oral administration of immediate-release carvedilol tablets, with an absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7669550-adcc-4e70-83b1-c28ce75e7fda (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a82149f-aade-2a9b-e053-2995a90a9daf (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e68c9b18-e7fd-45f7-a8f5-1d815e32680b (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbec7c4b-3db7-4c9d-b5da-e72050ee5743 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Carvedilol is rapidly and extensively absorbed following oral administration of immediate-release carvedilol tablets, with an absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55a19ff1-f8c1-4cf0-8711-9bfa32756de9 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e31271aa-259b-caa6-e053-2995a90a0fcd (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe4aa7f0-6ef2-4a95-8a64-5e3365f10474 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcb1de7c-1878-1835-e053-6294a90abe95 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:947baca7-f9c8-4821-b47b-53c45288613e (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd8b2a3f-c2fa-4859-84a1-c02f2b608748 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df7415ac-e475-19c9-e053-2995a90afa71 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol Tablet is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c34847d-68f9-4967-81c8-a2297a6acb7f (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b23021d4-c00a-e0ef-eb93-1dc824ae56ca (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4e700f8-d0e0-4ad5-93b5-e935389a96e3 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:196536eb-8b94-45da-a2f3-f554d6bf88e9 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33dfcf29-19d6-46ba-b8ed-d59d2226ad07 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol Tablet is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07c619c6-4a0c-445e-94fa-664a54f68a39 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics COREG is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52785a22-ddca-4f5b-8579-5974df2a9a4e (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d3937b4-e0dd-4165-9825-bbf5020d79f9 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e453c21-a8a8-dc54-5591-74c972d41727 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0089df4-37c8-41de-810c-14c9dc06f0c3 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bfea06d-7abe-407a-80a4-d15d373569f7 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcb2025f-11a1-ea73-e053-6394a90a61cb (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:325dae60-01ce-a120-e063-6294a90a2ef2 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Carvedilol is rapidly and extensively absorbed following oral administration of immediate-release carvedilol tablets, with an absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7d6bfff-fbb6-4a1f-aa13-babbb9a1e878 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4a21f67-7812-4634-beba-f8e85c63c5f2 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6ab5da0-8f22-491d-b007-85d9d4901828 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
It also increases levels of atrial natriuretic peptide. 12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:444ee05c-571a-4ea6-8763-af05d252df56 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c8d54e6-835c-4fa7-b13b-b798916cfed3 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39cf31cc-8f3d-4919-a93a-f997ad6850dc (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee848543-12fb-446c-86db-bf2322ec986f (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffbedcce-0d64-4aed-9e65-09448d71ca91 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0202d0f-2ffc-45f2-a98d-5f05ac1eaa85 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7cc14b86-0833-4c3c-91f3-7963d7052fd5 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3f463b5-2743-4a4a-a90a-bf1ee10a5458 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol Tablet is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68c275e8-992a-4520-8065-ab6d615d89cc (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a97a2467-7525-467c-8969-38246903690c (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:205da5d0-05d9-440d-bb5a-b30b826900ab (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:441dda59-c3c4-d3c6-e063-6394a90a98dc (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol Tablet is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a7d3ca1-05b0-4c7e-aefa-492cc441585d (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45233e64-26ee-4117-a896-24363b435fc2 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol Tablet is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc6a2d33-aa04-4a04-9cde-901b744d24ca (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3eb4fd8e-1027-4d24-8f2f-12e9dcfe6231 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e285434f-d831-b6e7-e053-2995a90a1ab2 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7aae1a4a-5d0e-4b19-9e4c-55707a9bb184 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol Tablet is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed11cd4e-d7c9-8446-e053-2995a90afd6e (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da8b8c20-0130-4aa9-924d-4a4f28c3f767 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fb46fe1-9b7b-4718-9327-2471af22f0b7 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5b907f8-84a0-5fb2-e7ec-4c82246195f5 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58337744-a130-35ef-e063-6294a90a080b (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9959f5d7-c363-4b8d-b8b9-7b45a8cb9aa9 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3697789e-ed17-4433-af94-e8ea19d8e04d (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Carvedilol is rapidly and extensively absorbed following oral administration of immediate-release carvedilol tablets, with an absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21191d89-16f6-49a8-9394-f31d0950deea (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol Tablet is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:205291ba-86a7-43e1-be47-bc75df1921f9 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
It also increases levels of atrial natriuretic peptide. 12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3724c7f1-dd2a-4bc9-b388-17238d663860 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2a0407c-2e05-60eb-e053-2a95a90abc99 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:786e8ad3-a8d7-41e6-e053-2991aa0a32c7 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da830b08-1cdd-4d36-a068-c376fd7763c4 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c462ce0b-486d-4599-ba60-b836781779d3 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Carvedilol is rapidly and extensively absorbed following oral administration of immediate-release carvedilol tablets, with an absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0930965b-80e3-4a0c-bffc-14ac32a47894 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df600dde-8ef9-52e3-e053-2a95a90a2dc0 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5eeeaeee-9698-493f-9aa7-d13068147208 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol is rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5572c43-61fe-459f-a40a-5cd7f26d1ec4 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c0e089b-0199-43e2-e063-6394a90a7883 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
It also increases levels of atrial natriuretic peptide. 12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51b403dc-fc9f-0cad-e063-6394a90af081 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6eec3476-f6db-45bd-bb91-4b2d5fbd0f5f (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:683bd1c4-fb9d-46cc-9bd4-6a6e455cadfb (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Carvedilol tablets are rapidly and extensively absorbed following oral administration, with absolute bioavailability of approximately 25% to 35% due to a significant degree of first-pass metabolism.
Projected row 260
- Medicine slug
- carvedilol
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 123
- Source count
- 111
- Agreement rate
- 1
- Recorded readings
7 to 10 hours
- Numeric value
- 7
- Unit
- hours
- Source records
- 111
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 111 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe462198-32ae-4f6c-befc-acb97fb017c9 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b56e0d0-82d7-4512-849f-2b72d7bae36e (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:454054f1-0730-41b3-844a-c7b65f1b47c5 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c03bd9d7-1e0b-49da-a14a-32e712dc3a2d (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8ccf07f5-78fb-76da-e053-2a95a90a0090 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5822e3c-413c-4c7e-bbec-d0d42d2028ba (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:462a9678-d2cd-d2b8-e063-6294a90a0139 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c48ba6b-4e1e-5116-e063-6394a90aa793 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bd0f2596-a192-4b0e-836f-4a09816408a4 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eb892787-edd0-4ab6-aef2-2d0216384395 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52bd1d20-08ba-1e5e-e063-6294a90ae8a9 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc3a9614-3017-4775-988e-6e5bd4621b70 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84ee5fbf-7299-4b8a-e053-2a91aa0aa159 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac14846e-423a-37c4-e053-2a95a90a3cdd (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd7e7c34-6958-47be-a1c1-f1ed948e2687 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5e766e3-ef75-4100-e053-2995a90a510f (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8640adde-d071-44a4-97d0-fa8a8548debe (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c133b9c7-ab1a-e517-e053-2995a90a517a (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db5d9e64-46b3-92d3-e053-2995a90a74bc (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:574c419f-3b9e-2171-e063-6394a90a0e90 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58280d18-5960-1730-e063-6394a90a4f64 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:95300809-be15-461e-904e-b56aba676975 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:49afdf89-0bed-71da-e054-00144ff88e88 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:36230cc8-e808-4f74-a27d-4367eecd21f7 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0ae5bed-1cb4-45d6-befe-dfc68edb9b34 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7bfd0fc-054b-7397-e053-2a95a90ae3e2 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da2696ba-f4be-4626-9abe-fe33f36361b1 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2be8635b-5733-1ed4-e054-00144ff88e88 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8db9cddd-0ee7-4ce8-a8c9-c5e043b2838a (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ddff189-1848-4186-bca9-063e4ea7fd1f (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32098c09-7580-4975-a3e1-31b619c04c69 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e98593a-8424-48c8-acc0-671f4b566aee (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a570b8ea-530d-4565-a091-bb9dbe4a6d8d (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5969d18-46c7-4f35-9668-2fd4f6bbeb17 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b0887c72-bc6a-010d-e053-2995a90aab8d (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:157f64c6-2c21-4056-b643-79047ca237a9 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:add1ee3d-fca4-4301-b871-7dda6eda7bb7 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bbf3767-8666-22d8-e063-6294a90a2afe (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:010290af-81f4-0037-e063-6394a90a4638 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:03b7c07c-14ba-40c8-8c0a-8dfa4a10f580 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec6d8d73-9d18-4a9e-ae0c-0ea12059e78e (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab8aa773-0ed1-4d59-a1bb-f46cf882644f (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe2d5c95-c101-4b01-89fd-0fd6d25ad80b (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed60e2e4-6eda-4728-aec4-263b821e4ed8 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1344411-fc64-4233-89ba-e90a1953e150 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81bc612d-5674-45b9-a1f5-2cb4fa625747 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64ba2b17-989e-443c-8277-9649489b5ce8 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0617fa4-1e87-48fa-947a-e4249153a947 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7669550-adcc-4e70-83b1-c28ce75e7fda (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a82149f-aade-2a9b-e053-2995a90a9daf (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e68c9b18-e7fd-45f7-a8f5-1d815e32680b (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55a19ff1-f8c1-4cf0-8711-9bfa32756de9 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e31271aa-259b-caa6-e053-2995a90a0fcd (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe4aa7f0-6ef2-4a95-8a64-5e3365f10474 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcb1de7c-1878-1835-e053-6294a90abe95 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:947baca7-f9c8-4821-b47b-53c45288613e (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd8b2a3f-c2fa-4859-84a1-c02f2b608748 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df7415ac-e475-19c9-e053-2995a90afa71 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c34847d-68f9-4967-81c8-a2297a6acb7f (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b23021d4-c00a-e0ef-eb93-1dc824ae56ca (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4e700f8-d0e0-4ad5-93b5-e935389a96e3 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:196536eb-8b94-45da-a2f3-f554d6bf88e9 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33dfcf29-19d6-46ba-b8ed-d59d2226ad07 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:07c619c6-4a0c-445e-94fa-664a54f68a39 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52785a22-ddca-4f5b-8579-5974df2a9a4e (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d3937b4-e0dd-4165-9825-bbf5020d79f9 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e453c21-a8a8-dc54-5591-74c972d41727 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d0089df4-37c8-41de-810c-14c9dc06f0c3 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bfea06d-7abe-407a-80a4-d15d373569f7 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcb2025f-11a1-ea73-e053-6394a90a61cb (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d7d6bfff-fbb6-4a1f-aa13-babbb9a1e878 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4a21f67-7812-4634-beba-f8e85c63c5f2 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6ab5da0-8f22-491d-b007-85d9d4901828 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:444ee05c-571a-4ea6-8763-af05d252df56 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c8d54e6-835c-4fa7-b13b-b798916cfed3 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39cf31cc-8f3d-4919-a93a-f997ad6850dc (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee848543-12fb-446c-86db-bf2322ec986f (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ffbedcce-0d64-4aed-9e65-09448d71ca91 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0202d0f-2ffc-45f2-a98d-5f05ac1eaa85 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7cc14b86-0833-4c3c-91f3-7963d7052fd5 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e3f463b5-2743-4a4a-a90a-bf1ee10a5458 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68c275e8-992a-4520-8065-ab6d615d89cc (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a97a2467-7525-467c-8969-38246903690c (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:205da5d0-05d9-440d-bb5a-b30b826900ab (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:441dda59-c3c4-d3c6-e063-6394a90a98dc (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7a7d3ca1-05b0-4c7e-aefa-492cc441585d (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45233e64-26ee-4117-a896-24363b435fc2 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc6a2d33-aa04-4a04-9cde-901b744d24ca (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3eb4fd8e-1027-4d24-8f2f-12e9dcfe6231 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e285434f-d831-b6e7-e053-2995a90a1ab2 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7aae1a4a-5d0e-4b19-9e4c-55707a9bb184 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed11cd4e-d7c9-8446-e053-2995a90afd6e (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da8b8c20-0130-4aa9-924d-4a4f28c3f767 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2fb46fe1-9b7b-4718-9327-2471af22f0b7 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5b907f8-84a0-5fb2-e7ec-4c82246195f5 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58337744-a130-35ef-e063-6294a90a080b (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9959f5d7-c363-4b8d-b8b9-7b45a8cb9aa9 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21191d89-16f6-49a8-9394-f31d0950deea (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:205291ba-86a7-43e1-be47-bc75df1921f9 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3724c7f1-dd2a-4bc9-b388-17238d663860 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2a0407c-2e05-60eb-e053-2a95a90abc99 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:786e8ad3-a8d7-41e6-e053-2991aa0a32c7 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da830b08-1cdd-4d36-a068-c376fd7763c4 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0930965b-80e3-4a0c-bffc-14ac32a47894 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df600dde-8ef9-52e3-e053-2a95a90a2dc0 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5eeeaeee-9698-493f-9aa7-d13068147208 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5572c43-61fe-459f-a40a-5cd7f26d1ec4 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c0e089b-0199-43e2-e063-6394a90a7883 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51b403dc-fc9f-0cad-e063-6394a90af081 (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6eec3476-f6db-45bd-bb91-4b2d5fbd0f5f (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:683bd1c4-fb9d-46cc-9bd4-6a6e455cadfb (opens source in a new tab)
Carvedilol label
Version not recorded · Effective date not recorded
Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=250Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.